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During the first 100 years of Alzheimer’s disease re-
search, this devastating and intractable disorder has
been characterized at the clinical, histological, and
molecular levels. Nevertheless, many key mechanistic
questions remain unanswered. Here we will empha-
size the importance of the cell biology of Alzheimer’s
disease, reviewing the relevant literature that has
expanded our mechanistic understanding, with a par-
ticular focus on pathways regulating protein sorting.
Accumulated evidence indicates that sorting path-
ways may be uniquely vulnerable to disease patho-
genesis, and recent studies have begun to reveal
disease-related defects in the regulation of protein
sorting.
One hundred years ago, Alois Alzheimer examined the
brain of Auguste D., a demented woman who began de-
veloping cognitive deficits in her late 40s, and thereby
established that dementia can be associated with neu-
rofibrillary tangles and amyloid plaques (Alzheimer
et al., 1995 [an English translation of 1907 article by
Alzheimer et al.]). In 1910, Emile Kraepelin defined
‘‘Alzheimer’s disease’’ as a distinct dementing illness,
which, he maintained, provided evidence that dementia
can have an ‘‘organic’’ etiology (Schorer, 1985). Yet, for
decades thereafter, the major dementia of late life was
either dismissed as the inevitable endstage of normal
aging or else attributed to ‘‘cerebral atherosclerosis’’
(Katzman, 1986). Over fifty years would pass before in-
vestigators began appreciating that late-onset (‘‘senile’’)
dementia and early-onset (‘‘pre-senile’’) Alzheimer’s
disease are phenotypically indistinguishable under the
microscope, prompting the unification of the disorders
under the same name (Amaducci et al., 1986).
Nevertheless, despite a shared name and overlapping
features, the early-onset and late-onset forms of Alz-
heimer’s disease are epidemiologically and etiologically
distinct (Mayeux, 2003; Bertram and Tanzi, 2005). The
early-onset form is extremely rare and is caused by
monogenic defects that follow an autosomal-dominant
pattern (Mayeux, 2003; Bertram and Tanzi, 2005). Like
other autosomal-dominant diseases, early-onset Alz-
heimer’s disease has proven amenable to linkage analy-
sis, and many pathogenic mutations have been isolated.
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net (S.G.)In contrast, late-onset Alzheimer’s disease, which typi-
cally manifests after the sixth decade, accounts for
over 95% of all cases and has a complex etiology
(Mayeux, 2003; Bertram and Tanzi, 2005). Like other
complex disorders, the cause of late-onset Alzheimer’s
disease has been difficult to pinpoint. Indeed, the late-
onset form has historically been called ‘‘sporadic’’ Alz-
heimer’s disease to reflect the elusiveness of its etiol-
ogy. Not only is late-onset disease the more common
form of Alzheimer’s disease, but with increased longev-
ity, late-onset Alzheimer’s disease has emerged as one
of the most common disorders of the brain (Small and
Mayeux, 2000).
Whereas the 20th century began with the histological
description of Alzheimer’s disease, the century ended
with its genetic and molecular characterization. This
era began in 1984 when amyloid-b (Ab) was isolated as
the core peptide of amyloid plaques (Glenner and
Wong, 1984; Masters et al., 1985) and entered full swing
when, in 1986, the gene encoding the peptide’s parent
protein, the amyloid precursor protein (APP), was iden-
tified (Goldgaber et al.,1987; Kang et al., 1987; Robakis
et al., 1987; Tanzi et al., 1987). APP turned out to be
a type-I transmembrane protein (Kang et al., 1987),
and fine chromosomal mapping of APP revealed its
localization to the Down’s syndrome region of chromo-
some 21 (Tanzi et al., 1987), a particularly intriguing dis-
covery since trisomy 21 (Down’s syndrome) invariably
causes early-onset Alzheimer’s disease (Wisniewski
et al., 1978). Then, in 1990 and 1991, linkage analyses re-
vealed that mutations in APP can cause either early-on-
set Alzheimer’s disease (Goate et al., 1991) or hereditary
cerebrovascular amyloidosis (Dutch type) (Levy et al.,
1990), and missense mutations were localized within
or adjacent to the Ab domain of APP (Levy et al.,
1990). Although disease-causing mutations in APP oc-
cur in only a handful of families, these findings provided
the strongest evidence that the disease can be initiated
by abnormalities in APP processing and the accumula-
tion of Ab peptide (reviewed in Hardy and Allsop, 1991;
Hardy and Higgins, 1992; Haass and Selkoe, 1993; and
Tanzi and Bertram, 2005).
Further reaffirming the relevance of APP processing to
the disease, in 1995, additional mutations causing early-
onset Alzheimer’s disease were isolated in two unknown
genes encoding complex, polytopic proteins (Sherring-
ton et al., 1995; Rogaev et al., 1995; Levy-Lahad et al.,
1995a, 1995b). Since these genes cause early-onset,
‘‘pre-senile,’’ Alzheimer’s disease, they were named
presenilin 1 and presenilin 2, and they were localized
to chromosome 14 and chromosome 1, respectively.
Mutations in presenilins 1 and 2 modify APP processing
by shifting the relative generation of Ab species so as to
increase the Ab42/Ab40 ratio (where the number indi-
cates the amino-acid length of each peptide species)
(Borchelt et al., 1996; Duff et al., 1996; Scheuner et al.,
1996; Citron et al., 1997). Ab42 oligomerizes more rap-
idly than other forms of Ab (Hilbich et al., 1991; Burdick
et al., 1992; Jarrett et al., 1993), and Ab oligomers appear
particularly toxic to neurons (reviewed in Klein et al.,
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16Figure 1. Protein Sorting as a Key Mecha-
nism in Alzheimer’s Cell Biology
(A) Ab (red bar) is liberated from its parent
protein, APP (multicolor bar), in two enzy-
matic steps. In the first b-cleavage step,
BACE (blue bar) splits full-length APP into
an sAPPb fragment (brown bar) and a C-ter-
minal fragment (CTFb, red/green bar). Then,
in the g-cleavage step, the g-secretase
(star) splits CTFb into Ab (red bar) and amy-
loid intracellular domain (AICD, green bar).
b-cleavage is the committed step in APP pro-
cessing and may be upregulated in late-onset
Alzheimer’s disease.
(B) Both APP (red bar) and BACE (blue bar)
are type-I transmembrane proteins that are
sorted through multiple membranous com-
partments of the cell. The sorting triangle
that interconnects the trans-Golgi network
(TGN), cell surface, and the endosome is crit-
ically important for APP and BACE sorting. As
indicated, clathrin is the coat complex that
regulates transport from the cell surface and
the TGN to the endosome, while the retromer
is the coat complex that regulates transport
from the endosome back to the TGN. A con-
vergence of findings suggests that APP and
BACE are most likely to interact within the
membranes of the endosomal system, initiat-
ing the potentially amyloidogenic pathway.2001; see also Lesne et al., 2006). Finally, in 1999–2000
this productive era was capped off with the isolation of
b-site APP cleaving enzyme (BACE), a transmembrane
protease that governs the first enzymatic step in APP
processing, known as b-secretase cleavage or simply
b-cleavage (Vassar et al., 1999; Sinha et al., 1999; Lin
et al., 2000).
When the knowledge of the pathogenic mutations for
early-onset disease were taken together with other dis-
coveries related to APP metabolism, the basic biochem-
ical formula for Ab production was established (Fig-
ure 1A) (for review, see Gandy, 2005). The Ab domain
is located within APP at the junction between the intra-
lumenal and transmembrane domains. Two enzymatic
steps liberate Ab from APP. In the first, ‘‘b-cleavage’’
step, BACE cleaves APP at or near the N terminus of
the Ab peptide; then, in the second, or ‘‘g-cleavage’’
step, the membrane-bound C-terminal APP fragment
(CTF) generated by BACE goes on to be cleaved by
the g-secretase, a multimeric complex thought to be
made up of an essential quartet of transmembrane pro-
teins—presenilin 1 (or 2), nicastrin, APH1, and PEN2
(Edbauer et al., 2003; Kimberly et al., 2003; Takasugi
et al., 2003). Recent evidence indicates that a fifth mole-
cule, TMP21, is also associated with the g-secretase
complex and plays a regulatory role in g-cleavage
(Chen et al., 2006).
Knowing the biochemical formula for Ab production is
sufficient to explain the Ab accumulation observed in
early-onset Alzheimer’s disease. Nevertheless, these
molecular defects do not exist in late-onset Alzheimer’s
disease and therefore cannot explain the accumulation
of both Ab40 and Ab42 that characterize the common
form of the disease. In reality, of course, Ab production
occurs in living neurons, not in a cell-free biochemical
reaction. Pursuing the cell biology of how and where inthe cell APP is processed has expanded the list of pos-
sible mechanisms that regulate Ab production and has
suggested pathogenic possibilities that extend beyond
simple molecular defects in APP or the secretases. In
this regard, it is notable that APP and the secretases
are all integral transmembrane proteins; that they are
dynamically sorted through the plasma membrane and
the membranes of intracellular organelles; and that the
liberation of Ab involves a transmembrane secretase en-
zyme acting on a transmembrane APP CTF substrate.
Thus, from a cell biology perspective, sorting mecha-
nisms that cause APP and the secretases to colocalize
in the same membranous compartment would be ex-
pected to play important roles in the regulation of Ab
production.
Over 30% of all proteins are transmembrane proteins
(Cobbold et al., 2003), and most are typically sorted
via the secretory and endocytic pathways (Figure 1B)
(Le Borgne and Hoflack, 1998; Harter and Reinhard,
2000). During the last two decades, great strides have
been made in understanding the molecular mechanisms
that govern transmembrane protein sorting. The trans-
Golgi network (TGN) and the endosome have emerged
as especially key ‘‘waystation’’ organelles, where the
complex movement of transmembrane proteins is
orchestrated, particularly in polarized cells such as neu-
rons (Ponnambalam and Baldwin, 2003; Gleeson et al.,
2004; Rodriguez-Boulan and Musch, 2005). Contributing
to their importance, a bidirectional pathway exists
between these two organelles, providing the only direct
intracellular link between the secretory and endocytic
pathways (Figure 1) (Le Borgne and Hoflack, 1998).
(Note: the ‘‘endosome’’ is, of course, not a singular
organelle, but rather is made up of multiple subtypes—
including the early endosome, the sorting endosome,
the recycling endosome, the late endosome, and the
Review
17Figure 2. Coat Complexes in Alzheimer’s
Disease
The clathrin coat (left). The clathrin coat com-
plex transports type-I transmembrane pro-
teins to the endosome from the TGN or from
the cell surface. Each clathrin molecule is
made up of three clathrin light chains (CLC)
and three clathrin heavy chains (CHC). The
terminal domains of CHC binds adaptor pro-
teins (blue), which in turn bind the to-be-
sorted transmembrane cargo proteins (gray
bar). The adaptor proteins impose cargo
and itinerary specificity. The dileucine motif
found in BACE typically binds GGAs, a family
of adaptor proteins engaged in clathrin-medi-
ated transport from the TGN to the endo-
some. The NPXY motif found in APP binds
a wide-range of adaptor proteins (as
discussed in the text) engaged in clathrin-
mediated transport from the cell surface to
the endosome.
The retromer (middle and right panels). The retromer coat complex transports type-I transmembrane proteins from the endosome to the TGN.
VPS35 is the core of the retromer and binds directly to the to-be-transported type-I transmembrane protein cargo (gray bar). VPS26, VPS29, and
sortin nexins (SNX) 1 or 2 assemble onto VPS35 to generate the complete functional retromer complex. Recent findings suggest that the retromer
sorts APP or BACE, either by direct binding to the retromer or by indirect binding to the transmembrane adaptor protein sorLA (blue).multivesicular body. Nevertheless, for purposes of clar-
ity, unless otherwise specified, we will use the term ‘‘en-
dosome’’ to encompass all subtypes.)
Because of the importance of the trafficking pathways
interconnecting theTGN, cell surface,and theendosome,
investigators have sought to elucidate many of the basic
mechanisms governing protein transport through this
itinerary (for review, see Bonifacino and Rojas, 2006). In
particular, the sorting signals contained within trans-
membrane proteins and the specific coat complexes
that initiate transport through each leg of this sorting itin-
erary have been characterized (Kreis and Pepperkok,
1994). The discovery of key findings about the cell biology
ofprotein sorting has chronologically trackedwith molec-
ular discoveries related to Alzheimer’s disease. For ex-
ample, in 1990, the asparagiNe-Proline-any-tYrosine
(N-P-X-Y) motif in the cytoplasmic tail of type-I trans-
membrane proteins was identified as an evolutionarily
conserved sorting signal that targets proteins for clathrin
pit localization and transport via clathrin-coated vesicles
from the cell surface to the endosome (Chen et al., 1990)
(Figure 2). APP, cloned 4 years earlier, was found to con-
tain this motif, immediately generating specific predic-
tions about its sorting itinerary. In a similar fashion, the
sorting of BACE was informed by later reports showing
that the D-X-X-L-L dileucine motif, present in the cyto-
plasmic tail of BACE, is a separate type of sorting signal
involved with clathrin-coat transport between the TGN
and endosome (He et al., 2005; Wahle et al., 2005). Most
recently, at the turn of the century and about the same
time that BACE was cloned, cell biological studies char-
acterized a novel coat complex, the retromer, involved
primarily in retrograde transport from the endosome
(Seaman, 2004; Bonifacino and Rojas, 2006), and the ret-
romer has recently been implicated in APP and BACE
sorting (Small and Kim, 2003; Small et al., 2003, 2005;
He et al., 2005).
The dovetailing ofstudies elucidating thegeneral mech-
anisms that regulate transmembrane protein sorting with
studies isolating the specific transmembrane proteins
related to Alzheimer’s disease has suggested potentialpathogenic pathways and forms the basis of this review.
We will first attempt to reconcile sometimes conflicting
findings and pinpoint the membranous compartments in
which neuronal APP is most commonly cleaved to gener-
ate discrete fragments. Next, we will review the known or
postulated sorting mechanisms that regulate the trans-
port of APP and the transmembrane secretase enzymes
through relevant pathways of the neuron. In so doing,
we will generate a list of sorting molecules that play roles
in Abbiogenesis and are therefore potential points for dis-
ease origins. Finally, we will end by reviewing recent find-
ings showing that defects in some of these sorting path-
ways exist in late-onset Alzheimer’s disease and may
contribute to its pathogenesis.
The Membranous Compartments in which APP
Is Cleaved
The First Enzymatic Step in the Amyloidogenic
Pathway: b-Cleavage
The earliest studies of b-cleavage were conducted in the
early 1990s, when b-cleavage and Ab generation were
discovered to accompany normal cellular metabolism
(Shoji et al., 1992; Seubert et al., 1992, 1993; Haass
et al., 1992). Both APP and BACE are sorted through
the secretory and endocytic pathways and reside, at
least transiently, in almost all membranous compart-
ments of these pathways. A number of early cell biology
studies suggested that the endocytic process and the
endosomal/lysosomal pathways contributed signifi-
cantly to Ab production (Caporaso et al., 1992a; Gandy
et al., 1992; Nordstedt et al., 1993; Caporaso et al.,
1994; Perez et al., 1996; Ono et al., 1997; Marquez-
Sterling et al., 1997; Soriano et al., 1999).
Madin-Darby canine kidney (MDCK)-based systems
were applied to the study of polarization of APP traffick-
ing and sorting, as models for similar events that go on in
neuronal cells (Haass et al., 1994, 1995a; Capell et al.,
2002). In MDCK cells, apical sorting is often associated
with proteins destined for axonal transport, while baso-
lateral sorting is often associated with somatodendritic
destinations (Ahn et al., 1996). In the MDCK system,
Neuron
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both of which are generated intracellularly (Ahn et al.,
1996). BACE, however, is apically sorted, where Ab gen-
eration is limited (Capell et al., 2002). When a relative ex-
cess of APP is provided to the apical surface, a substan-
tial fraction of that APP is converted to Ab (Capell et al.,
2002). This situation was considered potentially relevant
to neurons since APP was known to be highly targeted
for axonal transport (Koo et al., 1990). These data from
MDCK cells tended to predict that, since APP and
BACE may be targeted for axonal transport to nerve ter-
minals, the presynaptic nerve terminal might be an es-
pecially efficient site for Ab generation. The identity of
the particular b-cleavage-competent organelle most rel-
evant to the pathogenesis of Alzheimer’s disease has
been a matter of debate. Kindling this debate were ap-
parently discrepant findings in studies reporting that
Ab production could be demonstrated in the cultured
cell to occur, alternately, in the ER, in the TGN, or in
the endosome (Haass et al., 1995b; Chyung et al.,
1997; Cook et al., 1997; Greenfield et al., 1999; Skovron-
sky et al., 2000a; Petanceska et al., 2000).
Many factors contributed to the difficulty in resolving
which of these compartments was most likely responsi-
ble for generation of the Ab that causes pathology. Since
BACE was only isolated and cloned in 1999, the task of
localizing where BACE activity resides in the cell in stud-
ies from the 1990s could only be inferred based on indi-
rect evidence. An example is the chemical poisoning of
specific organelles with compounds such as brefeldin A
and monensin and then determining how this manipula-
tion affected the profile of intracellular and secreted APP
fragments (Caporaso et al., 1992a, 1992b, 1994).
More generally, however, since they are both trans-
membrane proteins, APP and BACE do in fact reside,
at least temporarily, in multiple organelles. It is impor-
tant to emphasize that the mechanisms that sort trans-
membrane proteins are very much dependent on spe-
cific experimental conditions, and thus methodological
differences across studies might shift the sites where
APP and BACE interact. Methodological differences,
therefore, probably account for some apparently dis-
crepant findings in early cell culture studies investigat-
ing the cell biology of APP processing. One important
source of variability is that studies often differed in
whether wild-type or Swedish (K670N/M671L) mutant
APP was transfected into cells under investigation.
Since the Swedish mutation in particular enhances the
efficiency of BACE cleavage of APP (Citron et al.,
1992), metabolism of this mutant yields particularly ro-
bust generation of Ab. For this reason, many investiga-
tors, past and present, have studied the cell biology of
Swedish mutant APP. However, as compared to wild-
type APP, Swedish APP is cleaved by BACE in more
proximal compartments that are probably not identical,
at least on a quantitative stoichiometric basis, to those
where wild-type APP is cleaved by BACE (Haass et al.,
1995b; Perez et al., 1996, 1999; Sodhi et al., 2004).
Thus, while there was early agreement that most Swed-
ish APP is b-cleaved in the TGN, there remained uncer-
tainty about where most wild-type APP was b-cleaved.
Furthermore, there was always the concern that artifi-
cially overexpressing APP or BACE might artifactually
shift the locus of APP processing.The isolation and cloning of BACE provided a much-
needed experimental handle with which the cell biology
of its interaction with APP could be investigated. A de-
tailed analysis of the sorting itinerary of BACE provided
clear evidence that mature BACE is found predomi-
nantly in the endosome, with relatively lower levels dis-
tributed among the cell surface and the TGN (Huse
et al., 2000). Virtually no mature BACE is found in the ly-
sosome or in the endoplasmic reticulum (Huse et al.,
2000). The relative absence of BACE in the lysosome
was important, since biochemical studies suggested
that BACE activity is maximized in an acidic environ-
ment. Thus, the possibility that the lysosome was an
important site for b-cleavage was excluded.
Based on the cellular localization of BACE alone, the
site of b-cleavage was narrowed down significantly,
leaving open the possibility that important b-cleavage
occurs in the TGN, the cell surface, the endosome, or
in the sorting pathways that connect these sites. Among
the remaining possibilities, the endosome and the endo-
cytic pathway are the most acidic, making these sites
best suited for BACE activity. Nevertheless, the rela-
tively subtle pH difference between endosomes and
the TGN does not by itself provide sufficient evidence
to resolve this important issue. In support of earlier find-
ings, recent studies have shown that blocking endo-
cytosis reduces Ab production (Carey et al., 2005),
whereas enhancing endocytosis favors its production
(Grbovic et al., 2003), thus confirming that the endocytic
pathway can play an important role in APP processing.
However, these studies do not rule out the importance
of the TGN and the secretory pathway for b-cleavage.
Only by explicitly comparing each of the three mem-
brane compartments can a more definitive answer be
provided. Indeed, the results of a number of recent stud-
ies seem to converge on the endocytic pathway as the
one in which most b-cleavage of wild-type APP is
most likely to occur. A recent study that directly tested
for sites of BACE-APP interactions employed fluores-
cence resonance energy transfer (FRET) analysis, argu-
ably the best technique for studying protein-protein in-
teractions in living cells (Kinoshita et al., 2003). This
study showed that wild-type APP binds BACE with
greatest efficiency in the endosome, less so on the cell
surface, and to a negligible degree in the TGN and secre-
tory pathway (Kinoshita et al., 2003). Interestingly, an in-
crease of APP:BACE binding was observed in the TGN
when the Swedish mutant form of APP was investigated,
agreeing with the earlier evidence that b-cleavage of
Swedish mutant APP occurs preferentially within the
TGN (Haass et al., 1995b).
In summary, although the interaction of APP with
BACE can, in principle, occur in the ER, in the TGN, on
the cell surface, in the endosome, or along the sorting
pathways interconnecting them, the preponderance of
circumstantial and direct evidence suggests that, for
wild-type APP, b-cleavage probably occurs most com-
monly in the endosome and the endocytic pathway.
The Second Enzymatic Step in the Amyloidogenic
Pathway: g-Cleavage
Identifying the membranous site in which g-secretase
cleaves the carboxyl-terminal fragment of APP, the final
step in liberating the Ab peptide, has been even
more controversial than localizing the cleavage site for
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19b-cleavage. As discussed above, the fact that b-cleav-
age turned out to be governed by a monomeric protein
greatly simplified the search for its site of action. In con-
trast, not only is the g-secretase a multimeric complex,
made up of multiple proteins or protein fragments, but
there is still debate about whether its full complement
of component elements has been established. Although
most studies agree that the presenilins are components
of the g-secretase, there are a number of experimental
and biological reasons to explain why mapping the cel-
lular location of the presenilins might not necessarily
indicate the site of g-cleavage. First, compared to en-
dogenous patterns, overexpressing exogenous prese-
nilins appears to shift their subcellular location (Thina-
karan et al., 1996; Lee et al., 1997; Lah et al., 1997).
Second, there is coordinated regulation of trafficking
of various g-secretase components (Zhang et al., 2005;
Niimura et al., 2005). As a result, expressing presenilins
with and without the other putative elements of the
g-secretase complex (nicastrin, APH1, PEN2) also shifts
the membranous compartment in which presenilins or
the other g-secretase components are concentrated
(Zhang et al., 2005; Niimura et al., 2005). Third, g-secre-
tase activity is dependent on membrane-bound cleaved
fragments of presenilin, and presenilin fragments may
exist in different compartments compared to the holo-
protein (Petanceska et al., 2000), which is itself a zymo-
gen and therefore is inactive until it is cleaved.
Thus, since simple protein localization studies are dif-
ficult to interpret, localizing g-secretase activity, while
indirect, may be more informative in identifying sites in
which g-cleavage occurs. In this regard, it is notable
that a number of studies have established that g-cleav-
age can occur in the presynaptic terminal of the neuron
(Kamenetz et al., 2003). Components of the TGN are
specifically excluded from the axon and axon hillock
(Caporaso et al., 1994). Therefore, among the organelles
implicated in g-cleavage, the endosome is the only key
Ab-generating intracellular organelle that exists in the
presynaptic terminal, therefore suggesting that endo-
somes, or the transport pathways into endosomes, con-
tain the molecular machinery necessary for both b- and
g-cleavage (Koo et al., 1990; Ikin et al., 1996; Marquez-
Sterling et al., 1997; Lah et al., 1997; Buxbaum et al.,
1998a). Pathogenically, a convergence of findings sug-
gests that Ab biogenesis in the nerve terminal is the pro-
cessing site of APP that is most relevant to the patho-
physiology of Alzheimer’s disease in patients (Arnold
et al., 1991; Beach and McGeer, 1992; Rogers and
Morrison, 1985) and in mouse models of disease (Bux-
baum et al., 1998a; Lazarov et al., 2002; Sheng et al.,
2002; Lee et al., 2005). Thus, based on the site within
the neuron in which both b- and g-cleavage occurs, it
can be inferred that the g-secretase is active, in a patho-
genically relevant manner, in the endosome or endocytic
pathway (Lah and Levey, 2000; Fukumori et al., 2006).
Indeed, recent studies using a reporter system that cou-
ples g-secretase cleavage to generation of a fluorescent
signal shows unequivocally that, in cultured cells, most
g-cleavage, and hence, most Ab generation, occurs in
endosomes (Kaether et al., 2006).
Lipids appear to play important roles in APP process-
ing. Lipid rafts, perhaps within endosomal membranes,
may act by coordinating the proximity of APP, BACE,and g-secretase (Riddell et al., 2001; Ehehalt et al.,
2003; Cordy et al., 2003; Vetrivel et al., 2004, 2005).
The role of cholesterol in APP metabolism has received
much attention, and a proper review of that literature
would occupy far more space than is allotted here. Suf-
fice it to say that there are many important observations
relating cholesterol to APP metabolism, but elucidation
of the basis for that link has been challenging and
frustrating. Polymorphisms in the major cholesterol
transport protein, apolipoprotein E, specify risk for
Alzheimer’s in as many as 25%–30% of cases of the
common form of Alzheimer’s (Strittmatter et al., 1993;
Corder et al., 1993; Schmechel et al., 1993). Choles-
terol-lowering drugs decrease Ab levels released from
cultured neurons (Simons et al., 1998) and attenuate
Ab accumulation in the brains of plaque-forming trans-
genic mice (Refolo et al., 2000, 2001). Surprisingly, how-
ever, the use of genetic manipulation to lower circulating
cholesterol levels has no effect on brain Ab (Fagan et al.,
2004). Clearly, additional investigation will be required
before one can develop a satisfactory and parsimonious
model for the relationship between cholesterol and Ab.
From a clinical perspective, the link between cholesterol
and Alzheimer’s is being tested in a large, placebo-con-
trolled, double-blind clinical trial in which the potential
for the cholesterol-lowering drug simvastatin to slow
the progression of Alzheimer’s is being evaluated. Cer-
tainly, if the simvastatin trial is positive, this will provide
enormous impetus for a redoubled effort toward ex-
plaining the ‘‘Alzheimer-cholesterol connection.’’
Sorting Mechanisms in Alzheimer’s Disease
Delivering transmembrane proteins to their precise
intracellular destinations is of critical importance to the
biology of the cell, and it is therefore not surprising
that a growing number of sorting mechanisms are being
described, dedicated to the faithful execution of this
complex process (van Vliet et al., 2003). Defects in the
sorting protein sorCS1 have recently been associated
with increasing risk for another complex disorder,
type-2 diabetes mellitus (Clee et al., 2006). For the next
section of this review, we will be guided by the sorting
itinerary proven important for APP processing. As a re-
sult, we will restrict our focus to the sorting mechanisms
governing transport among the TGN, cell surface, and
endosome. Specifically, since they are monomeric pro-
teins, the sorting of APP and BACE is best understood.
Therefore, we will review known or postulated sorting
mechanisms involved in the transport of AP and BACE.
Vesicular Transport of APP and BACE
Coat complexes play critical roles in the budding of
transport vesicles off donor membrane compartments
that initiates the process of transmembrane protein
sorting. Based on the sorting motifs expressed in APP
and BACE, these proteins were predicted to be trans-
ported by the clathrin coat complex (Bonifacino and
Traub, 2003). Clathrin proteins are constructed from
three heavy chains and three light chains (Hirst and Rob-
inson, 1998). Clathrin does not bind directly to its cargo,
but rather, the globular tail of each clathrin heavy chain
binds ‘‘adaptor’’ proteins, which, in turn, bind to the cy-
toplasmic tails of the transmembrane protein cargo
(Hirst and Robinson, 1998). Clathrin coats are involved
in two main sorting routes—the endocytic pathway
Neuron
20connecting the cell surface to the endosome, and the
pathway connecting the TGN to the endosome (Traub,
2005) (Figure 1). While identical clathrin proteins are in-
volved in different sorting pathways and in sorting differ-
ent transmembrane proteins, it is the variety of adaptor
proteins that is believed to be responsible for imposing
sorting specificity at the stage of cargo selection (Hirst
and Robinson, 1998).
As mentioned above, the cytoplasmic tail of APP con-
tains the NPXY amino acid motif, a motif that is evolu-
tionarily conserved and which governs the targeting of
cargo to clathrin-coated vesicles (Chen et al., 1990) (Fig-
ure 2). Motifs such as this are important for generating
predictions about sorting events. However, direct ex-
perimental proof of these predictions is required before
these sorting itineraries are established. Indeed, muta-
genesis studies have been used to assess and confirm
that each of the amino acids within the NPXY motif plays
some role in the process of transporting APP from the
cell surface to the endosome (Chen et al., 1990). A num-
ber of families of adaptor proteins have been found to
mediate the binding of the NPXY motif to clathrin coats.
Accordingly, a growing number of clathrin adaptor pro-
teins have been found to bind APP’s NPXY motif and
therefore serve as regulators of APP endocytosis. These
adaptor proteins include the autosomal-recessive
hypercholesterolemia (ARH) protein (Noviello et al.,
2003), disabled family member (Dab) 1 (Homayouni
et al., 1999), c-Jun N-terminal kinase interaction (Jip1b)
protein (Inomata et al., 2003; Matsuda et al., 2001;
Scheinfeld et al., 2002), members of the Fe65 family (in-
cluding Fe65, Fe65L1, and Fe65L2) (Fiore et al., 1995;
Borg et al., 1996; Bressler et al., 1996; Guenette et al.,
1996; Zambrano et al., 1997; Duilio et al., 1998; Tanaha-
shi and Tabira, 1999), and members of the X11 family of
proteins, in particular X11a (Borg et al., 1996; McLough-
lin et al., 1999; Tomita et al., 1999). In many instances,
these adaptors reduce generation of Ab by causing
APP to spend more residence time at the plasma mem-
brane or within the ER (Watanabe et al., 1999; Sabo
et al., 1999).
In contrast to the NPXY signal within the APP cyto-
plasmic tail, BACE expresses a dileucine sorting motif
in the corresponding domain (Rapoport et al., 1998).
This sorting motif also binds the clathrin coat complex;
however, transmembrane proteins that express the di-
leucine motif are typically transported through the path-
way that directly connects the TGN and the endocytic
system (Figure 2) (Boman, 2001; Bonifacino, 2004). The
reason for this different sorting itinerary is attributed to
the Golgi-localized g-ear-containing ARF-binding
(GGA) family of adaptor proteins, including GGA1,
GGA2, and GGA3 (Boman, 2001; Bonifacino, 2004).
GGA1 appears to be the GGA subtype that controls
BACE transport from the endosome to the TGN. GGA
proteins express a VPS-27, Hrs, and STAM (VHS) do-
main that binds the dileucine motif of BACE (Boman,
2001; Bonifacino, 2004). Localized mainly in the TGN
and less so in endosomes, GGAs are involved in sorting
transmembrane proteins away from the TGN and toward
the endosome. Somewhat surprisingly, some, though
not all, studies suggest that BACE is transported from
the endosome to the TGN through GGA-mediated sort-
ing (He et al., 2005).The retromer is the second coat complex implicated in
the transport of BACE (Figure 2) and perhaps APP as well
(Small and Kim, 2003; Small et al., 2003, 2005; He et al.,
2005) (Figure 2). First described in yeast, the retromer
is a newly characterized coat complex, made up of
VPS35, VPS26, VPS29, VPS5, and VPS17 (VPS = Vacuo-
lar Protein Sorting), which, in yeast, serves to sort the
type-I transmembrane protein VPS10 from the endo-
some back to the TGN (Seaman et al., 1998; Edgar and
Polak, 2000; Haft et al., 2000; Nothwehr et al., 2000;
Pfeffer, 2001; Reddy and Seaman, 2001; Seaman and
Williams, 2002). The name ‘‘retromer’’ is derived from
the role of this coat in retrograde sorting itineraries.
VPS35 serves as the core of the retromer complex, bind-
ing not only the other retromer elements, but also binding
the cytoplasmic tail of the transmembrane protein cargo
that is being sorted (Figure 2) (Reddy and Seaman, 2001).
Except for VPS17, mammalian (including human) ho-
mologs of retromer molecules have been identified
(Haft et al., 2000) and are highly expressed in the brain.
VPS35, VPS26, and VPS29 have single mammalian ho-
mologs, which are known by the same names (Haft
et al., 2000). Recent studies suggest that VPS26 has
two isoforms, termed VPS26a and VPS26b (Kerr et al.,
2005). VPS5 has two mammalian homologs, known as
sorting nexin 1 and sorting nexin 2 (Haft et al., 2000). Be-
cause of these homologies, the retromer was predicted
to mediate the sorting of type-I transmembrane proteins
in mammals. In 2004, this prediction was confirmed
when a number of groups established that the retromer
is involved in transporting type-I transmembrane pro-
teins such as the cationic-independent mannose-6-
phosphate receptor (Arighi et al., 2004; Seaman, 2004)
and the polymeric immunoglobulin G receptor (Verges
et al., 2004). Furthermore, these studies suggested
that another molecule, known as sortilin, is also trans-
ported by the mammalian retromer (Seaman, 2004).
This observation is particularly interesting since sortilin
is one of the five known type-I transmembrane proteins
that express VPS10, the primary cargo of the yeast ret-
romer (Hampe et al., 2001), suggesting functional ho-
mologies between the yeast and mammalian retromer.
The other members of this family are known as sorLA
(also known as LR11), sorCS1, sorCS2, and sorCS3
(Hampe et al., 2001).
Although the retromer is highly expressed in the brain,
until recently, the type-I transmembrane proteins trans-
ported by the neuronal retromer were unknown. The first
clues about which type-I transmembrane proteins might
be sorted by the neuronal retromer came from a study
exploring microarray data generated from human brain
tissue (Small and Kim, 2003; Small et al., 2003). Among
a list of possible retromer cargo molecules, this study
demonstrated that sorLA and BACE were among the
type-I transmembrane molecules whose expression
levels cross-correlated most strongly with levels of neu-
ronal VPS35 (Small and Kim, 2003; Small et al., 2003).
Although this cross-correlation approach has been
successfully used in microarray studies to identify mol-
ecules that are candidates for interacting with one an-
other (Bhardwaj and Lu, 2005), these predictions can,
of course, only be used as a screen whose results re-
quire confirmation by direct experimental investigation.
Direct evidence that the retromer plays a role in BACE
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siRNA to knock down VPS26 in cell culture (He et al.,
2005). This manipulation, which was originally used in
the studies implicating the retromer in mannose-
6-phosphate receptor sorting, reduces both VPS26
and VPS35 levels, causing retromer dysfunction (Arighi
et al., 2004; Seaman, 2004; Verges et al., 2004). By
knocking down VPS26, retromer dysfunction was
shown to missort BACE as manifested by an increase
in endosomal BACE (He et al., 2005). Experimental con-
firmation regarding interaction of VPS35 with sorLA has
not yet been provided. Nevertheless, since sorLA has
close homologies to sortilin, its VPS10-containing family
member, one would plausibly speculate that sorLA is
also sorted by the neuronal retromer. Interestingly,
a number of studies have shown that sorLA binds APP
and BACE (Andersen et al., 2005; Offe et al., 2006).
Therefore, sorLA and perhaps other VPS10-containing
molecules might function as the equivalent of an adap-
tor protein, binding the retromer complex to cargo pro-
teins such as APP (Figure 2). Of note, although some
studies suggest that GGAs transport BACE along the
same sorting pathway—from the endosome to the
TGN—there is no evidence that GGA and retromer sort-
ing interact or compete with each other.
Whereas coat complexes begin the process of trans-
membrane sorting by forming transport vesicles at the
donor membrane compartment, the process ends, of
course, when the cargo travels over its route and suc-
cessfully arrives at its destination membrane (Bonifa-
cino and Glick, 2004). It is worth noting that transport
vesicles typically travel over microtubule-supported
routes, and, therefore, any process that interrupts the in-
tegrity of microtubules might affect transmembrane pro-
tein sorting. One major neuropathological feature of Alz-
heimer’s disease that is not discussed in detail here
involves accumulation of intracellular precipitates of
the cytoskeleton and formation of structures known as
neurofibrillary tangles (Alzheimer et al., 1995). While a
discussion of neurofibrillary tangle pathogenesis is be-
yond the scope of this review, the fact that the major tan-
gle protein, tau, is a microtubule-binding protein merits
mention in this review of protein sorting (see Geschwind,
2003, for review).
The fusion of a transport vesicle to the membrane of
the targeted organelle completes the process of trans-
membrane protein sorting, and this fusion step is
governed by three main families of proteins—soluble
N-ethylmaleimide sensitive factor-attachment protein
receptor (SNARE) proteins (Rothman, 1994), Rab (a sub-
family of the Ras superfamily of low-molecular-mass
GTPases) proteins (Novick and Zerial, 1997), and Sec1/
Munc18 (SM) proteins (Toonen and Verhage, 2003).
Membrane fusion and cargo delivery occur when
SNAREs expressed in the membranes of the transport
vesicle (e.g., syntaxins and vesicle-associated mem-
brane proteins [VAMPs]) interact with a single SNARE
protein expressed in the membrane of the recipient or-
ganelles, while the Rabs and SM proteins play important
roles in mediating this interaction. The fidelity of vesicu-
lar transport, in which vesicles are differentially deliv-
ered to their proper destinations, is governed by the
specific combination of SNARES, Rabs, and SM pro-
teins found in the receptor membranes. Although amongthese families of proteins, the specific combinations
have not yet been identified for the transport of APP
and BACE through the cell surface, endosome, and
TGN, a select group of these fusing proteins have
been implicating in this sorting itinerary. This list in-
cludes syntaxins 5, 6, 7, 8, 13, and 16 (Prekeris et al.,
1999); VAMPs 5, 7, and 8 (Prekeris et al., 1999); Rabs 5
and 11 (Pfeffer, 1999); the SM protein VPS45, Munc 13,
and Munc 18 (Toonen and Verhage, 2003; Rossner
et al., 2004).
Phosphorylation-State-Specific Sorting of APP
and BACE
The phosphorylation states of substrate proteins and
lipids also play roles in APP and BACE transport. The
phosphorylation states of membrane proteins such as
APP or BACE, and/or the phosphorylation states of their
specific interacting proteins, provide for dynamic regu-
lation of signal transduction and protein sorting on a mo-
ment-to-moment basis, thereby integrating protein sort-
ing and neurotransmission (Mostov and Cardone, 1995;
Clague and Urbe, 2001; Bonifacino and Traub, 2003). A
striking example is that of regulated ectodomain shed-
ding of APP (Buxbaum et al., 1990, 1992; Caporaso
et al., 1992b; Nitsch et al., 1992; Gillespie et al., 1992; Pe-
drini et al., 2005). During regulated shedding, first mes-
sengers such as neurotransmitters and hormones (Bux-
baum et al., 1992; Nitsch et al., 1992; Jaffe et al., 1994; Xu
et al., 1998; Qin et al., 2006) impinge upon neurons and
direct APP toward the cell surface and away from the
TGN and endocytic pathways (Xu et al., 1995), and
hence away from BACE. At the cell surface, APP can
be processed by a nonamyloidogenic pathway, known
as the a-secretase pathway and defined by the metallo-
proteinases ADAM-9, ADAM-10, and ADAM-17 (Bux-
baum et al., 1998b; Esler and Wolfe, 2001; Allinson
et al., 2003; Postina et al., 2004; Kojro and Fahrenholz,
2005). ADAM is an acronym derived from ‘‘a disintegrin
and metalloproteinase.’’ The molecular mechanism of
regulated shedding remains to be fully elucidated but
appears to involve phosphorylation of components of
the TGN vesicle biogenesis machinery (thereby increas-
ing APP delivery to the cell surface; Xu et al., 1995) as
well as phosphorylation of protein components of the
endocytic system (thereby blocking APP internalization;
Chyung and Selkoe, 2003; Carey et al., 2005). The phos-
phorylation states of APP and BACE do not appear to be
involved in this process (Gandy et al., 1988; Oishi et al.,
1997; da Cruz e Silva et al., 1993; Jacobsen et al., 1994;
Pastorino et al., 2002). With regard to Ab generation, this
phenomenon is noteworthy because hyperactivation of
the a pathway (e.g., with a combination of simultaneous
protein kinase activation and protein phosphatase inhi-
bition) can lead to relatively greater cleavage of APP by
a-secretase(s) (Caporaso et al., 1992b; Gillespie et al.,
1992), thereby reducing or completely abolishing Ab
generation (Buxbaum et al., 1993; Gabuzda et al.,
1993; Hung et al., 1993). Interest in this phenomenon
has recently been revived with the demonstration that
microdialysis techniques can be used to demonstrate
and quantify regulated shedding and regulated Ab gen-
eration in the brains of living experimental animals
(Cirrito et al., 2005; Selkoe, 2006).
Recent evidence suggests that axonal transport
of APP (Lee et al., 2003) and perhaps also prolyl
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phorylation of the APP cytoplasmic tail at threonine-668
(Pastorino et al., 2006). APP is axonally transported in
holoprotein form (Koo et al., 1990; Buxbaum et al.,
1998a); hence, the phosphorylation of threonine-668
was proposed to serve as a ‘‘tag,’’ targeting phospho-
forms of APP for delivery to the nerve terminal (Lee
et al., 2003). However, recent evidence calls into ques-
tion the proposal that the phosphorylation state of thre-
onine-668 plays a major physiological role in APP local-
ization or Ab generation, since threonine-to-alanine-668
knock-in mice show normal levels and subcellular distri-
butions of APP and its metabolites, including Ab (Sano
et al., 2006). There is compelling evidence, however,
that, once at the nerve terminal, APP is processed, gen-
erating Ab locally at the terminal and releasing Ab at,
near, or into the synapse (Kamenetz et al., 2003).
The cytoplasmic tail of BACE also undergoes revers-
ible phosphorylation, and that event appears to specify
its recycling (von Arnim et al., 2004; He et al., 2005). In
cell lines, the dephospho- and phospho-forms of
BACE appear to perform with similar efficiencies in gen-
erating Ab40 and Ab42 (Pastorino et al., 2002), but this
has not been evaluated in primary neuronal cultures.
This failure of Ab generation to be regulated by BACE re-
cycling is somewhat unexpected since, as reviewed
above, most Ab is believed to arise from the endocytic
pathway. Hence, one would expect that increasing
BACE concentration in the endocytic pathway would in-
crease generation of Ab. One explanation for this unex-
pected result is that substrate may be limiting in post-
TGN compartments, and therefore increased levels of
BACE are unable to raise Ab generation. This notion
agrees with the proposal mentioned above that regu-
lated shedding acts at the TGN to divert APP molecules
toward the plasma membrane as a means of lower gen-
eration of Ab at least in part because a limited pool of
APP is transported out of the TGN (Buxbaum et al.,
1993; Skovronsky et al., 2000b). Indeed, in some neuro-
nal-like cell types, over 80% of the newly synthesized
moles of APP are degraded without generating obvious
discrete metabolic fragments (Caporaso et al., 1992b).
Clathrin-independent endocytosis of transmembrane
proteins is regulated by protein phosphorylation (Rob-
ertson et al., 2006). Further, two components of the en-
docytosis machinery, dynamin and amphiphysin, con-
trol clathrin-mediated endocytosis in a fashion that is
sensitive to their direct phosphorylation by the protein
kinase cdk5 (Tomizawa et al., 2003; Nguyen and Bibb,
2003). Retromer function is regulated by a separate
complex of molecules known as ‘‘complex II’’ (Burda
et al., 2002). Complex II includes several catalytic func-
tions that direct retromer action. The phosphoinositide
kinase VPS34 binds the protein kinase VPS15, and
then, secondarily, VPS30 and VPS38 are recruited and
the four molecules comprise the complete complex II
(Burda et al., 2002). Thus, complex II action is modulated
not only by protein phosphorylation but also by lipid
phosphorylation (Stack et al., 1995). Some investigators
have proposed that the PI 3-kinase component of com-
plex II directs synthesis of a specific pool of endosomal
PI3, which, in turn, activates or stimulates assembly of
the retromer complex, thereby ensuring efficient endo-
some-to-Golgi retrograde transport (Stack et al., 1995).These regulatory mechanisms may have implications
for Ab generation, but such a connection, if one exists,
remains to be elucidated. Clearly, much remains to be
studied about the intricacies of retromer function and
dysfunction.
Presenilins and APP Sorting
Soon after the discovery of presenilins, gene targeting
experiments were performed in mice in order to investi-
gate the essential bioactivities of these complex, poly-
topic, molecules, especially presenilin 1 (PS1) (Wong
et al., 1997; Naruse et al., 1998). In cells from PS1-defi-
cient mice, delivery of multiple type-I proteins to the
cell surface was observed to be disturbed; APP and
the p75 neurotrophin receptor were among those mis-
sorted proteins (Naruse et al., 1998). This work was
somewhat overshadowed, however, when cells from
PS1-deficient mice were demonstrated to be incapable
of generating Ab (De Strooper et al., 1998). This observa-
tion placed APP and PS1 on a common metabolic path-
way for the first time and was rapidly followed by dem-
onstration that PS1 did, indeed, contain the catalytic
site of g-secretase, as established by cross-linking of
g-secretase inhibitors to PS1 (Li et al., 2000a, 2000b).
The unusual intramembranous localization of two as-
partate residues led to the postulation that these amino
acids were forming the active site of an aspartyl protein-
ase (Wolfe et al., 1999). This dovetailed with the appar-
ent fact that APP CTFs were cleaved by regulated intra-
membranous proteolysis (RIP), and when the aspartates
were mutated to alanines, g-secretase activity was abol-
ished (Wolfe et al., 1999). RIP was, at the time, a relatively
recently recognized phenomenon, and conventional
wisdom up to that point had held that the hydrophobic-
ity of membranes would preclude the entry of water into
the lipid bilayer to enable hydrolysis of peptide bonds.
Even to this day, the mechanism that provides the capa-
bility for surmounting that energy barrier is poorly under-
stood. The popular formulation at that point was that
PS1 was a proteinase, and the notion that PS1 was a traf-
ficking factor was underemphasized. The possibility
was also raised that perhaps aberrant trafficking in
PS1-deficient cells was due to the inability of some un-
identified PS1 substrate trafficking factor to function
properly in its uncleaved state since its cognate prote-
ase (PS1) was absent.
Beginning in the last few years, experiments in cul-
tured cells and cell-free assays have begun to yield
compelling evidence that PS1 serves a trafficking func-
tion in addition to its catalytic function. However, these
recent experiments have a common potential alternative
interpretation: i.e., the exact same processing effects
would be predicted in the event that key trafficking pro-
teins were important substrates for cleavage by PS1.
Therefore, when PS1 is deficient, post-TGN trafficking
of membrane protein cargos would become abnormal
due to deficient processing of the trafficking factor/PS
substrate (Kaether et al., 2002; Wang et al., 2004;
Wood et al., 2005; Rechards et al., 2006).
Most PS1-deficient mice and cells are highly compro-
mised and resemble Notch-deficient mice and cells
(Wong et al., 1997). This is not entirely unexpected since
Notch is a substrate for cleavage by g-secretase as are
another several dozen type-I transmembrane proteins,
including cadherin, erb-b4, and the p75 NGF receptor
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for review, see Fortini, 2002). Therefore, PS1 deficiency
can lead to dysfunction of a host of proteins whose
physiological function requires cleavage by RIP in order
to release their cytoplasmic domains. In many exam-
ples, the cytoplasmic domain released by g-secretase
appears to diffuse rapidly to the nucleus, where these in-
tracellular domains (ICDs) such as Notch intracellular
domain (NICD) modulate gene transcription (Cupers
et al., 2001; Fortini, 2002; Cao and Sudhof, 2001).
PS1-mediated trafficking appears to localize to post-
TGN steps of trafficking of type-I transmembrane pro-
teins (Annaert et al., 1999; Kaether et al., 2002; Cai
et al., 2003; Wang et al., 2004, 2006; Wood et al., 2005;
Zhang et al., 2006; Cai et al., 2006a, 2006b; S.G. et al.,
unpublished data). This role for PS1 in regulation of
APP trafficking has been implicated in both cell culture
and cell-free in vitro reconstitution studies (Annaert
et al., 1999; Kaether et al., 2002; Cai et al., 2003; Wang
et al., 2004, 2006; Wood et al., 2005; Zhang et al.,
2006; Cai et al., 2006a, 2006b; S.G. et al., unpublished
data). Pathogenic PS1 mutations retard egress of APP
from the TGN by a mechanism that appears to involve
phospholipase D (Cai et al., 2006a, 2006b), a known
TGN budding modulator (Kahn et al., 1993). It is clear
that the mutations that have been tested so far increase
the residence time at the TGN while also increasing the
Ab42/40 ratio (Kahn et al., 1993). Recent data suggest
that TGN retention per se can increase generation of
Ab42/40 in cerebral neurons in vivo, indicating that ab-
normal post-TGN trafficking of APP might be sufficient
to initiate Ab accumulation (S.G. et al., unpublished
data).
The pathogenic PS1 defect can be corrected in cell
culture and in cell-free systems following supplementa-
tion of the budding factor phospholipase D (PLD) (Cai
et al., 2003, 2006a, 2006b). The molecular details of
how PS1 and PLD are connected remain obscure; how-
ever, as cargos other than APP are found to be mis-
sorted, including, e.g., tyrosinase (Wang et al., 2006),
the notion that PS1 has a protein trafficking function
has become more widely appreciated and accepted.
Now, the challenge is to identify at the molecular level
those factors that selectively favor cleavage at the
Ab42-43 scissile bond.
PS1 has also been implicated in trafficking of APP and
perhaps its carboxyl-terminal fragments out of the en-
dosome (Zhang et al., 2006). Thus, PS1 dysfunction
could also result in retention of APP and CTFs within
the endocytic compartment, which, in turn, would favor
Ab generation. Thus, accumulating evidence implicates
PS1 in the regulation of APP trafficking. The possibility
exists that the local environment within the TGN or the
endocytic system contributes to misalignment of mu-
tant PS1 and APP carboxyl-terminal fragments, thereby
favoring generation of Ab42. Such a mechanism has
been implicated in other diseases (e.g., cystic fibrosis)
that are also caused by missense mutations in polytopic
proteins (Gentzsch et al., 2004).
Sorting Defects in Late-Onset Alzheimer’s Disease
As reviewed, the sorting of APP and BACE among the
membranous compartments of the TGN, cell surface,
and the endosome is a dynamic and highly regulatedprocess. Thus, even subtle sorting defects that would
slow the trafficking in and out of any individual membra-
nous compartment could, in principle, increase Ab
generation. Guided by the sorting mechanisms that
transport APP and BACE from the surface to the endo-
some, and from the endosome back to the TGN, a list
of candidate molecules can be generated in which an
abnormality could, in theory, contribute to the accumu-
lation of Ab found in late-onset Alzheimer’s disease
(Table 1).
In principle, manipulating any molecule on this list
might modulate Ab generation. Indeed, this predicted
effect has already been shown for many of the listed
molecules (e.g., Ho et al., 2002; Hill et al., 2003). To
date, however, only a few of these molecules have
been found to be defective in brain tissue harvested
from patients with late-onset Alzheimer’s disease.
VPS35, VPS26, and Beclin (the mammalian homolog of
VPS30) were recently implicated in a study that relied
on brain imaging to construct an a priori model predict-
ing how pathogenic molecules should behave—spa-
tially and over time (Small et al., 2005). This model was
used as a guide, first in generating gene-expression pro-
files with microarray technology from areas of the brain
most vulnerable (the entorhinal cortex) and relatively re-
sistant (the dentate gyrus) to late-onset Alzheimer’s dis-
ease, and second in analyzing the complex microarray
dataset. As discussed in a recent review, imaging-
guided microarray is an effective approach for address-
ing many of the analytic limitations inherent to profiling
gene expression patterns generated from postmortem
brains (Lewandowski and Small, 2005). sorLA (also
known as LR11), a fourth molecule on the list, was impli-
cated in a study that first used microarray technology to
profile the gene expression patterns of lymphocytes of
patients with late-onset Alzheimer’s disease and then
found that sorLA levels are reduced in affected brains
(Scherzer et al., 2004). Subsequently, experimental evi-
dence directly established a role for sorLA in APP traf-
ficking and Ab generation in endosomal compartments
(Andersen et al., 2005; Offe et al., 2006).
Although some of these identified molecules serve
multiple functions, they are all unified in playing a role
in the retromer trafficking pathway. As reviewed,
VPS35 and VPS26 are core molecules of the retromer
complex itself (Seaman, 2005); VPS30 interacts with ret-
romer-related phosphoinositide kinases, whose activity
Table 1. Molecules that Participate in Sorting APP and/or BACE
Coat complexes clathrin heavy chains, clathrin light
chains, VPS35, VPS26A, VPS26B,
VPS29, sorting nexin 1, sorting
nexin 2, ARF
Coat adaptors sorLA, sortilin, ARH, Numb, Dab1,
Dab2, Jip1b, Fe65, Fe65L1,
Fe65L2, X11a, GGA1, GGA2, GGA3
Factors for docking
and/or fusion
syntaxin 5, 6, 7, 8, 13, 16; VAMP 5, 7, 8;
Rab 5, 11; SM protein VPS45,
Munc 13, 18
Protein or lipid kinases,
phosphatases
PKA, PKC, ERK, cdk5, GSK3, ROCK1,
PP1, PP2A, PI3K, Akt, VPS30
(beclin)-VPS34-PI3K
Other factors presenilin 1, presenilin 2, nicastrin,
APH1, PEN2, lipid rafts, caveolin,
flotillin, cholesterol
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24Figure 3. Sorting Defects in Late-Onset
Alzheimer’s Disease
To date, a handful of sorting molecules in-
volved in APP and BACE transport (see Table
1) have been found to be downregulated in
the brains of patients with late-onset Alz-
heimer’s disease. Although serving multiple
functions, the identified molecules all play
potential roles in retromer-mediated trans-
port (blue box, retromer; black bar, type-I
transmembrane cargo protein transported
from the endosome to the TGN), suggesting
a model whereby endosome-to-TGN trans-
port is a sorting itinerary particularly vulnera-
ble to disease. When compared to normal
neurons (upper panel), neurons of Alz-
heimer’s patients (lower panel) are predicted
to have diminished transport of APP and/or
BACE (black bar) out of the endosome,
thereby increasing the colocalization of APP
and BACE in endosomes. This, in turn, could
lead to excess b-cleavage and excess gener-
ation of Ab.mediates the binding of the retromer complex to the en-
dosomal membrane (Seaman, 2005); and, sorLA is a pu-
tative cargo of the neuronal retromer (Small and Kim,
2003; Small et al., 2003).
Taken together, these studies suggest that the retro-
mer trafficking pathway might play a primary role in
Ab generation and the pathogenesis of late-onset
Alzheimer’s disease. Furthermore, since APP and/or
BACE (directly or indirectly via sorLA) (Figure 2) might
be trafficked by the retromer, this generates a specific
hypothesis for how Abmight be overproduced in the ab-
sence of defects in APP, BACE, or components of the
g-secretase. Namely, defects in the retromer trafficking
pathway are predicted to increase the residence time of
APP and/or BACE in the endosome, thereby increasing
the b-cleavage step of APP processing (Figure 3). In-
deed, a number of studies have suggested that b-cleav-
age is enhanced in late-onset disease (Fukumoto et al.,
2002; Holsinger et al., 2002; Johnston et al., 2005; Li
et al., 2004; Tyler et al., 2002; Yang et al., 2003).
Nevertheless, many questions remain about the retro-
mer trafficking pathway and Alzheimer’s disease. For
example, further confirmation is required to establish
whether the retromer affects the sorting of APP and/or
BACE and whether it does so by directly binding eitherof these type-I transmembrane proteins. Also, although
studies agree that sorLA modulates the production of Ab
and binds APP, there are discrepancies in the currently
existing data as to whether sorLA downregulation mis-
sorts APP to the TGN or to the endosome (Offe et al.,
2006; Spoelgen et al., 2006). Finally, the upstream mech-
anisms that cause the reductions in VPS35, VPS26,
VPS30, and sorLA have not yet been established. In
this regard, the reported mismatch between the levels
of VPS35 mRNA and protein (Small et al., 2005) suggests
that retromer elements might undergo accelerated deg-
radation in the disease state. Although a recent report
did not find disease-related polymorphisms for VPS26
(Riemenschneider et al., 2006), a pattern of accelerated
degradation is consistent with a genetic defect, sug-
gesting that polymorphisms in other retromer elements
might exist (Lewandowski and Small, 2005).
More generally, beyond implicating a specific path-
way, the recent convergence of evidence provides
proof-of-principle that protein sorting is a cell biological
mechanism that can contribute to late-onset Alz-
heimer’s disease. As a complex disorder, many molecu-
lar defects are expected to contribute to late-onset Alz-
heimer’s disease, and other sorting molecules on the list
are predicted to contribute to disease pathogenesis.
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Transmembrane protein sorting is a fundamental prop-
erty of normal cellular function, and it is therefore not
surprising that a growing number of diseases are found
to be associated with, or directly caused by, defects in
sorting molecules (Olkkonen and Ikonen, 2000; Cobbold
et al., 2003; Clee et al., 2006). On theoretical grounds,
because APP and its cleaving enzymes are trans-
membrane proteins, and because Ab liberation is a
membrane-dependent event, protein sorting is a cell
biological process uniquely vulnerable to Alzheimer’s
disease pathogenesis. Specifically, the trafficking of
APP and BACE among the TGN, cell surface, and endo-
some are predicted to be the sorting pathways most rel-
evant to Alzheimer’s disease. Indeed, recent studies
have begun confirming this prediction, isolating dis-
ease-related defects in protein sorting, and future stud-
ies are expected to identify additional defects that regu-
late the transport of APP and its cleaving enzymes
through its sorting itinerary (Table 1).
Elucidating the mechanisms that sort APP and the
secretases through the TGN, cell surface, and endo-
some has significantly expanded the understanding of
Alzheimer’s disease cell biology. More importantly, iso-
lating specific defects in protein sorting opens up unex-
plored therapeutic avenues, which optimistically, may
accelerate the development of effective treatments for
this devastating and intractable disease.
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